Tuesday, August 18, 2026
ExploreSearch
Finance Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agent Rollout Outpaces Data Trust and Readiness
Enterprise adoption of agentic AI is accelerating fast — Siemens deepening its NVIDIA partnership for self-verifying agentic AI in chip design, Manulife expanding its Microsoft AI-governance partnership, and a wave of infrastructure launches (NVIDIA GPU-accelerated data processing, Dell exascale storage, new AI chip generations) — even as a new Google Cloud survey shows the underlying data foundation isn't ready: companies have AI access to only 45% of their data on average, data laggards see access fall to 30% or less, and only about half of organizations trust their AI agents' decisions. Meanwhile, insider selling at enterprise-AI bellwether C3.ai (CEO Thomas Siebel offloading $4.8M in shares) hints at investor caution layered under the adoption hype.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,812
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,812 facts checked against source5,219 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Earnings callNasdaq· November 9, 2025

Eton Pharma (ETON) Q3 2025 Earnings Transcript

View original at nasdaq.com
Eton Pharma (ETON) Q3 2025 Earnings Transcript Image source: The Motley Fool. DATE Thursday, November 6, 2025 at 4:30 p.m…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Eton will launch at least two additional products in 2026

    80% confidence

  • ET600, if approved, would be the first oral liquid desmopressin formulation for pediatric central diabetes insipidus

    80% confidence

  • Eton is a company that prides itself on pricing products appropriately

    80% confidence

  • Less favorable payer mix in Q3 resulted in lower Incralex revenue per patient

    80% confidence

  • Harmonizing the US and EU Incralex label could potentially increase the Incralex market opportunity roughly fivefold

    80% confidence

  • $900,000 in Q3 revenue from finish goods Incralex sales in Europe and $2.4 million in semi-finished inventory supplied to Astevi are not expected to recur regularly

    80% confidence

  • Alkindi and Kindivy can combine for peak sales of more than $50 million with the current Kindivy label and ultimately higher levels if the label is expanded

    80% confidence

  • European patient registry data spanning 15 years supports Incralex safety and efficacy for IGF-1 levels between -2 and -3 standard deviations

    80% confidence

  • Less than 15% of the estimated 5,000 target patients have converted to Alkindi/Kindivy

    80% confidence

  • Core US adjusted gross margin excluding ex-US Incralex was just over 70% for Q3

    80% confidence

  • Q4 US product sales expected to grow sequentially versus Q3; total product sales may be flat or slightly decline due to nonrecurring ex-US Incralex revenue

    80% confidence

  • In late-stage discussions with two parties for potential acquisitions, hoping to get something done before the end of the year

    80% confidence

  • Estimated 5,000 US target patients for adrenal insufficiency franchise (Alkindi/Kindivy)

    80% confidence

  • Approximately 200 estimated US patients meet current Incralex label criteria

    80% confidence

  • FDA indicated they would be receptive to a label expansion for Kindivy revised formulation

    80% confidence

  • Eton can achieve gross margin north of 75% by 2028

    80% confidence

  • 2026 expected to show significant revenue growth, increased profitability, and margin expansion

    80% confidence

Cited in these Via News reports